Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E.

BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7.

2.

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z.

3.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Santos C, Azuara D, Viéitez JM, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar R.

Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082.

PMID:
30840064
4.

Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity?

Santoro C, Marco Del Castillo A, González-Gómez A, Monteagudo JM, Hinojar R, Lorente A, Abellás M, Vieitez JM, Garcia Martìn A, Casas Rojo E, Ruíz S, Barrios V, Luis Moya J, Jimenez-Nacher JJ, Zamorano Gomez JL, Fernández-Golfín C.

Eur Heart J Cardiovasc Imaging. 2019 Mar 4. pii: jez024. doi: 10.1093/ehjci/jez024. [Epub ahead of print]

PMID:
30830219
5.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Erratum in: Sci Rep. 2019 May 17;9(1):7706.

6.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
7.

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J.

Cancer Med. 2018 Nov;7(11):5382-5393. doi: 10.1002/cam4.1703. Epub 2018 Aug 19.

8.

New species of Dispio Hartman, 1951 and Streblospio Webster, 1879 (Polychaeta, Spionidae) from the coast of the Iberian Peninsula.

Delgado-Blas VH, DÍaz-dÍaz Ó, ViÉitez JM.

Zootaxa. 2018 Apr 18;4410(3):525-238. doi: 10.11646/Zootaxa.4410.3.6.

PMID:
29690137
9.

CISNE: An accurate description of dose-effect and synergism in combination therapies.

García-Fuente A, Vázquez F, Viéitez JM, García Alonso FJ, Martín JI, Ferrer J.

Sci Rep. 2018 Mar 21;8(1):4964. doi: 10.1038/s41598-018-23321-6.

10.

A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

Grávalos C, Carrato A, Tobeña M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limón ML, Safont MJ, Martínez de Castro E, García-Alfonso P, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

Clin Colorectal Cancer. 2018 Jun;17(2):e323-e329. doi: 10.1016/j.clcc.2018.02.004. Epub 2018 Feb 17.

PMID:
29551560
11.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

PMID:
29145602
12.

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.

Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, Echavarria I, Macias I, Mangas M, Visa L, Buxo E, Álvarez Manceñido F, Viudez A, Pericay C, Azkarate A, Ramchandani A, López C, Martinez de Castro E, Fernández Montes A, Longo F, Sánchez Bayona R, Limón ML, Diaz-Serrano A, Martin Carnicero A, Arias D, Cerdà P, Rivera F, Vieitez JM, Sánchez Cánovas M, Garrido M, Gallego J.

Br J Cancer. 2017 Sep 5;117(6):775-782. doi: 10.1038/bjc.2017.245. Epub 2017 Aug 1.

13.

Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases.

Aranda E, Aparicio J, Bilbao JI, García-Alfonso P, Maurel J, Rodríguez J, Sangro B, Vieitez JM, Feliu J.

Future Oncol. 2017 Oct;13(23):2065-2082. doi: 10.2217/fon-2017-0220. Epub 2017 Jul 13. Review.

PMID:
28703622
14.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

15.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

16.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11. No abstract available.

17.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e16.

18.

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S.

J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3.

PMID:
26847813
19.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.

Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R.

Clin Transl Oncol. 2015 Dec;17(12):972-81. doi: 10.1007/s12094-015-1434-4. Epub 2015 Dec 15.

20.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Grávalos C, Escudero P, Vera R, Aranda E, García-Alfonso P, Gallego-Plazas J, Lopez C, Pericay C, Arrivi A, Vicente P, Ballesteros P, Elez E, López-Ladrón A, Díaz-Rubio E.

Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15.

PMID:
25515656
21.

Erratum to: Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.

Jiménez-Fonseca P, Solis MP, Garrido M, Faez L, Rodriguez D, Ruiz AL, Sanchez Lorenzo ML, Uriol E, Menendez MD, Viéitez JM.

Clin Transl Oncol. 2015 May;17(5):416-7. doi: 10.1007/s12094-014-1262-y. No abstract available.

22.

Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.

Jiménez-Fonseca P, Solis MP, Garrido M, Faez L, Rodriguez D, Ruiz AL, Sanchez Lorenzo ML, Uriol E, Menendez MD, Viéitez JM.

Clin Transl Oncol. 2015 May;17(5):384-92. doi: 10.1007/s12094-014-1243-1. Epub 2014 Nov 27. Erratum in: Clin Transl Oncol. 2015 May;17(5):416-7.

23.

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.

Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ.

Expert Rev Anticancer Ther. 2014 Aug;14(8):887-900. doi: 10.1586/14737140.2014.915194. Epub 2014 Jun 23. Review.

PMID:
24953238
24.

Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma.

Fonseca PJ, Uriol E, Galván JA, Alvarez C, Pérez Q, Villanueva N, Berros JP, Izquierdo M, Viéitez JM.

Case Rep Oncol. 2013 Aug 24;6(2):441-9. doi: 10.1159/000354754. eCollection 2013.

25.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators.

Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

PMID:
23168366
26.

Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.

Vieitez JM, García-Carbonero R, Aparicio J, Feliu J, González-Flores E, Grande E, Pérez-Hoyos T, Salud A, Torres E, Valero M, Valladares-Ayerbes M, Díaz-Rubio E.

Clin Transl Oncol. 2011 Nov;13(11):798-804. doi: 10.1007/s12094-011-0736-4.

PMID:
22082644
27.

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ.

Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0.

PMID:
20709657
28.

Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.

Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M, Muñiz I, Blay P, Fernandez Y, Vieitez JM, Muriel C, Sanmamed M, Coto PP, Izquierdo M, Estrada E, Lacave AJ.

Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13.

PMID:
20464446
29.

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

Viéitez JM, Valladares M, Peláez I, de Sande González L, García-Foncillas J, García-López JL, García-Girón C, Reboredo M, Bovio H, Lacave AJ.

Invest New Drugs. 2011 Oct;29(5):1038-44. doi: 10.1007/s10637-010-9400-z. Epub 2010 Mar 6.

PMID:
20204674
30.

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.

Esteban E, Villanueva N, Muñiz I, Fernández Y, Fra J, Luque M, Jiménez P, Llorente B, Capelan M, Vieitez JM, Estrada E, Buesa JM, Jiménez-Lacave A.

Invest New Drugs. 2008 Feb;26(1):67-74. Epub 2007 Sep 5.

PMID:
17805486
31.

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.

Esteban E, de Sande JL, Villanueva N, Corral N, Muñiz I, Vieitez JM, Fra J, Fernández Y, Estrada E, Fernandez JL, Luque M, Jimenez P, Mareque B, Capellan M, Buesa JM, Lacave AJ.

Lung Cancer. 2007 Feb;55(2):173-80. Epub 2006 Oct 27.

PMID:
17070962
32.

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.

Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON).

Invest New Drugs. 2006 May;24(3):241-8.

PMID:
16096704
33.

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination.

Esteban-Gonzalez E, Fernández Y, Villanueva N, Fra J, Muñiz I, Palacio I, Vieitez JM, Uña E, Mareque B, Lacave AJ.

Invest New Drugs. 2005 Dec;23(6):597-601.

PMID:
16034519
34.

The macroinfauna of the Galician sandy beaches (NW Spain) affected by the Prestige oil-spill.

Junoy J, Castellanos C, Viéitez JM, de la Huz MR, Lastra M.

Mar Pollut Bull. 2005 May;50(5):526-36. Epub 2004 Dec 19.

PMID:
15907495
35.

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M.

Ann Oncol. 2005 Jul;16(7):1081-6. Epub 2005 Apr 25.

PMID:
15851406
36.

Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.

Sánchez R, Esteban E, Palacio I, Fernández Y, Muñiz I, Vieitez JM, Fra J, Blay P, Villanueva N, Uña E, Mareque B, Estrada E, Buesa JM, Lacave AJ.

Invest New Drugs. 2003 Nov;21(4):459-63.

PMID:
14586214
37.

Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Esteban E, González de Sande L, Fernández Y, Corral N, Fra J, Muñiz I, Vieitez JM, Palacio I, Fernández JL, Estrada E, Lacave AJ; Grupo Oncológico del Norte de España.

Ann Oncol. 2003 Nov;14(11):1640-7.

PMID:
14581272
38.

Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.

Esteban E, Modollel A, González de Sande L, Palacio I, Muñiz I, Fernández Y, Corral N, Fra J, Sala M, Vieitez JM, Estrada E, Lacave AJ; Grupo Oncológico del Norte de España.

Breast Cancer Res Treat. 2003 Aug;80(3):257-65.

PMID:
14503798
39.

Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.

Viéitez JM, Carrasco J, Esteban E, Fra J, Alvarez E, Muñiz I, Sala M, Buesa JM, Jiménez Lacave A.

Am J Clin Oncol. 2003 Apr;26(2):107-11.

PMID:
12714877
40.

Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.

Vieitez JM, Valladares M, Gracia M, Gonzalez-Barón M, Martín G, Mel JR, Rodríguez R, Constenla M, Gómez Aldavarí JL, Domínguez S, Dorta J, García-Girón C, López R, Sevilla I, Esteban E, Antón LM, Peláez I, López E, Lacave AJ.

Lung Cancer. 2003 Jan;39(1):77-84.

PMID:
12499098
41.

Spionidae (Annelida: Polychaeta) from the Parque Nacional Morrocoy, Falcón, Venezuela.

Bone D, Viéitez JM.

Rev Biol Trop. 2002 Mar;50(1):69-75.

PMID:
12298268
42.

Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.

Esteban E, Fra J, Sala M, Carrasco J, Corral N, Vieitez JM, Estrada E, Palacio I, Buesa JM, Lacave AJ.

Invest New Drugs. 2002 Aug;20(3):317-26.

PMID:
12201494
43.

Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer.

Esteban E, Fra J, Corral N, Valle M, Carrasco J, Sala M, Puerta J, Estrada E, Palacio I, Vieitez JM, Buesa JM, Lacave AJ.

Invest New Drugs. 2002 Feb;20(1):73-82.

PMID:
12003196
44.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group.

J Clin Oncol. 2001 Nov 1;19(21):4097-106.

PMID:
11689577
45.

A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.

Esteban E, de Sande G, Puertas J, Fra J, Palacio I, Vieitez JM, Fernández JL, Muñiz I, Modollel A, Carrasco J, Sala M, Lacave AJ.

Breast Cancer Res Treat. 2000 Jul;62(2):127-33.

PMID:
11016750
46.

Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer.

Estaban E, Lacave AJ, Fernández JL, Corral N, Buesa JM, Estrada E, Palacio I, Vieitez JM, Muñiz I, Alvarez E.

Breast Cancer Res Treat. 1999 Nov;58(2):141-50.

PMID:
10674879
47.

High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.

Fernández-Hidalgo OA, Vanaclocha V, Vieitez JM, Aristu JJ, Rebollo J, Gúrpide A, Aramendía JM, Moreno-Palanques R, Martín-Algarra S, Subirá ML, Brugarolas A.

Bone Marrow Transplant. 1996 Jul;18(1):143-9.

PMID:
8832007
48.

Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.

González-Manzano R, Vieitez JM, Tangco E, Fernandez de Alava E, Herranz P, Garcia-Foncillas J.

Am J Clin Oncol. 1993 Aug;16(4):332-7.

PMID:
8328412
49.

Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma.

Hidalgo OF, Rebollo J, Vieitez JM, Bilbao I, Tangco E, Abuchaibe O, Pardo F.

Am J Clin Oncol. 1993 Feb;16(1):30-3.

PMID:
8424401
50.

Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer.

Hidalgo OF, Gonzalez FG, Vieitez JM, Rebollo J, Tangco E, Herranz P.

Ann Oncol. 1992 Jul;3(7):545-7.

PMID:
1498075

Supplemental Content

Loading ...
Support Center